1. Scrip
  2. >>COVID-19

Lilly’s Neutralizing Antibodies Reduce Risk Of Serious COVID-19 Outcomes By 70%

 
• By Joseph Haas

The bamlanivimab/etesevimab combo, filed for US emergency authorization in November, shows ability to reduce risk of hospitalization or death in COVID-19 patients. Lilly also sees prevention role for bamlanivimab.

Antibodies immunoglobulins attacking coronavirus covid-19 influenza virus cell, 3D immune system medical illustration background. Corona virus 2019-ncov sars cell, igm. Coronavirus sars-cov-2 disease
Lilly says two-antibody regimen against COVID-19 provides significant risk reduction for hospitalization, death

Eli Lilly and Company unveiled data from a trial of more than 1,000 high-risk COVID-19 patients on 26 January that bolsters its case for its neutralizing antibody duo to be deployed to prevent the risk of hospitalization or death in people infected by the novel coronavirus. One noteworthy datapoint showed that no patients who received the regimen died, compared to 10 patients in the placebo group.

Bamlanivimab (LLY-CoV555), co-developed by Lilly and AbCellera Biologics Inc., obtained emergency use authorization (EUA) on 9 November from the US Food and Drug Administration as treatment for mild-to-moderate cases of COVID-19 infection. (Also see "Coronavirus Update: Lilly’s Antibody EUA Adds To ‘Turnaround’ Hopes On Pandemic" - Scrip, 10 November, 2020

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’